The Future may be Closer Than you Think: A Response from the Personalized Medicine Coalition to the Royal Society’s Report on Personalized Medicine

• Anthony D : Diagnosis and screening of coronary artery disease.Prim. Care32, 931–946 (2005).
   PubMed Web of Science ®Google Scholar
• Sweetenham JW : Diffuse large B-cell lymphoma: risk stratification and management of relapsed disease.Hematology (Am. Soc. Hematol. Educ. Program)252–259 (2005).
   PubMedGoogle Scholar
• Valk PJ , VerhaakRG, BeijenMA et al.: Prognostically useful gene-expression profiles in acute myeloid leukemia.N. Engl. J. Med.350, 1617–1628 (2004).
   PubMed Web of Science ®Google Scholar
• Bullinger L , DohnerK, BairE et al.: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia.N. Engl. J. Med.350, 1605–1616 (2004).
   PubMed Web of Science ®Google Scholar
• Lonning PE , SorlieT, Borresen-DaleAL: Genomics in breast cancer – therapeutic implications.Nature Clin. Pract. Oncol.2, 26–33 (2005).
   PubMedGoogle Scholar
• Murphy N , MillarE, LeeCS: Gene expression profiling in breast cancer: towards individualising patient management.Pathology37, 271–277 (2005).
   PubMed Web of Science ®Google Scholar
• Nevins JR , HuangES, DressmanH et al.: Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction.Hum. Mol. Genet12(Spec. No 2), R153–R157 (2003).
   PubMed Web of Science ®Google Scholar
• Paik S , ShakS, TangG et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.N. Engl. J. Med.351, 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van’t Veer LJ et al.: A gene expression signature as a predictor of survival in breast cancer.N. Engl. J. Med.347, 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Liew CC : Expressed genome molecular signatures of heart failure.Clin. Chem. Lab. Med.43, 462–469 (2005).
   PubMed Web of Science ®Google Scholar
• Newby LK , GoldmannBU, OhmanEM: Troponin: an important prognostic marker and risk-stratification tool in non-ST-segment elevation acute coronary syndromes.J. Am. Coll. Cardiol.41, 31S–36S (2003).
   PubMed Web of Science ®Google Scholar
• Babuin L , JaffeAS: Troponin: the biomarker of choice for the detection of cardiac injury.CMAJ173, 1191–1202 (2005).
   PubMed Web of Science ®Google Scholar
• Eichelbaum M , Ingelman-SundbergM, EvansWE: Pharmacogenomics and individualized drug therapy.Annu. Rev. Med.57, 119–137 (2006).
   PubMed Web of Science ®Google Scholar
• Lewis R : An individual approach.Nature436, 746–747 (2005).
   PubMedGoogle Scholar
• Newell DR : How to develop a successful cancer drug – molecules to medicines or targets to treatments?Eur. J. Cancer41, 676–682 (2005).
   PubMed Web of Science ®Google Scholar
• Penny MA , McHaleD: Pharmacogenomics and the drug discovery pipeline: when should it be implemented?Am. J. Pharmacogenomics5, 53–62 (2005).
   PubMedGoogle Scholar
• Grice GR , SeatonTL, WoodlandAM et al.: Defining the opportunity for pharmacogenetic intervention in primary care.Pharmacogenomics7, 61–65 (2006).
   PubMed Web of Science ®Google Scholar
• Sequist LV , HaberDA, LynchTJ: Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.Clin. Cancer Res.11, 5668–5670 (2005).
   PubMed Web of Science ®Google Scholar
• Need AC , MotulskyAG, GoldsteinDB: Priorities and standards in pharmacogenetic research.Nature Genet.37, 671–681 (2005).
   PubMed Web of Science ®Google Scholar
• Jain KK : Applications of AmpliChip™ CYP450.Mol. Diagn.9, 119–127 (2005).
   PubMedGoogle Scholar
• Carlson JJ , HenriksonNB, VeenstraDL et al.: Economic analyses of human genetics services: a systematic review.Genet. Med.7, 519–523 (2005).
   PubMed Web of Science ®Google Scholar
• Phillips KA , Van Bebber SL: Measuring the value of pharmacogenomics.Nature Rev. Drug Discov.4, 500–509 (2005).
   PubMed Web of Science ®Google Scholar
• Hornberger J , CoslerLE, LymanGH: Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.Am. J. Manag. Care11, 313–324 (2005).
   PubMed Web of Science ®Google Scholar
• Deng MC , EisenHJ, MehraMR et al.: Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling.Am. J. Transplant6, 150–160 (2006).
   PubMed Web of Science ®Google Scholar
• Tavadia SM , MydlarskiPR, ReisMD et al.: Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case.J. Am. Acad. Dermatol.42, 628–632 (2000).
   PubMed Web of Science ®Google Scholar
• Marra CA , EsdaileJM, AnisAH: Practical pharmacogenetics: the cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine.J. Rheumatol.29, 2507–2512 (2002).
   PubMed Web of Science ®Google Scholar
• Oh KT , AnisAH, BaeSC: Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea.Rheumatology (Oxford)43, 156–163 (2004).
   PubMed Web of Science ®Google Scholar
• Clunie GP , LennardL: Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.Rheumatology (Oxford)43, 13–18 (2004).
   PubMed Web of Science ®Google Scholar
• Dubinsky MC , ReyesE, OfmanJ et al.: A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine.Am. J. Gastroenterol.100, 2239–2247 (2005).
   PubMed Web of Science ®Google Scholar
• Frueh FW , GurwitzD: From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community.Pharmacogenomics5, 571–579 (2004).
   PubMed Web of Science ®Google Scholar
• Lazarou J , PomeranzBH, CoreyPN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.JAMA279, 1200–1205 (1998).
   PubMed Web of Science ®Google Scholar
• Frueh FW , GoodsaidF, RudmanA et al.: The need for education in pharmacogenomics: a regulatory perspective.Pharmacogenomics J.5, 218–220 (2005).
   PubMed Web of Science ®Google Scholar
• Abbott A : Icelandic database shelved as court judges privacy in peril.Nature429, 118 (2004).
   PubMedGoogle Scholar
• Zerhouni EA : US biomedical research: basic, translational, and clinical sciences.JAMA294, 1352–1358 (2005).
   PubMed Web of Science ®Google Scholar

Websites

• The Royal Society: Personalised medicine: hopes and realities. www.royalsoc.ac.uk/displaypagedoc.asp?id=15874
   Google Scholar
• Genomics at US FDA webpage. www.fda.gov/cder/genomics/default.htm
   Google Scholar
• US Department of Health and Human Services press release: New Federal Health Initiative to Improve Cancer Therapy. www.fda.gov/bbs/topics/news/2006/NEW01316.html
   Google Scholar